Technology
Health
Biotechnology
Natera
$22.839876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$22.83
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.10 (0.44%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell Natera and other stocks, options, ETFs, and crypto commission-free!
About
Natera, Inc. engages in the discovery, development, and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test, Horizon Carrier Screening, Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis, Anora Products of Conception and Non-Invasive Paternity Testing. Read More The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in San Carlos, CA.
Employees
975
Headquarters
San Carlos, California
Founded
2003
Market Cap
1.45B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
670.10K
High Today
$23.31
Low Today
$22.67
Open Price
$22.84
Volume
148.18K
52 Week High
$29.62
52 Week Low
$11.08
Collections
Technology
Health
Biotechnology
2015 IPO
US
North America
News
Yahoo FinanceMay 22
Natera, Inc. Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in Natera, Inc. NTRA. The stock has moved higher by 24.3% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path. We certainly think that this might be the case, particularly if you consider NTRA’s recent earnings estimate revision activity. From this look, the company’s future is quite favorable; as NTRA has ear...
Yahoo FinanceMay 21
Noridian Posts Favorable Draft Local Coverage Determination for Natera's Prosperaâ„¢ Kidney Transplant Test
Represents Major Commercialization Milestone SAN CARLOS, Calif., May 21, 2019 /PRNewswire/ -- Noridian, the Medicare Administrative Contractor (MAC) for California-based laboratories, has posted a favorable draft local coverage determination (LCD) for use of Natera 's Prosperaâ„¢ test to assess active rejection in kidney transplant recipients. Natera, Inc. Logo (PRNewsFoto/Natera, Inc.) Scroll to continue with content Ad In its LCD, Noridian states, "Prospera is an effective, non-invasive method of assess...
Yahoo FinanceMay 20
OncoCyte Catches Eye: Stock Jumps 7.3%
OncoCyte Corporation OCX was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $4.04 to $5.08 in the past one-month time frame. The company has seen one negative estimate revision in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also...
Price Paid on Robinhood
26% Higher
Right Now
52 Week Low
$11.08
Average Price Paid
$18.05
52 Week High
$29.62
Earnings
-$0.85
-$0.72
-$0.59
-$0.46
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Aug 7, After Hours